Abzena PLC Appointment of Non-Executive Director (0907R)
September 19 2017 - 1:01AM
UK Regulatory
TIDMABZA
RNS Number : 0907R
Abzena PLC
19 September 2017
Abzena plc
Abzena appoints Lotta Ljungqvist as Non-Executive Director
Cambridge, UK, 19 September 2017 - Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), a life sciences group providing services
and technologies to enable development and manufacture of
biopharmaceutical products, announces that Lotta Ljungqvist has
today been appointed as a Non-Executive Director of the
Company.
Lotta Ljungqvist has a broad range of commercial and directorial
experience. She currently holds a dual role as President and CEO of
GE Nordics, responsible for GE's growth in all sectors across the
region. She is also CEO of BioProcess Innovation Hub, a government
initiative, where she has been setting up a new facility aiming to
support biotechnology companies in Scandinavia.
Before taking on the dual role at GE Nordics she spent eight
years with GE Healthcare Life Sciences as its Global Head of
R&D BioProcess. During this time, the division doubled in size
due to a series of acquisitions.
Prior to this, Lotta was CEO of a start-up Biotech, IMED AB,
based on research from the Karolinska Institute. She also worked at
Biovitrum AB for six years, as SVP, Biopharmaceutical Process
Development, selling cell culture, purification and analytical
services to the biopharmaceutical sector.
Lotta has held several board positions including her current
position as Non-Executive Director on the board of Atlas
Antibodies, a privately held manufacturer and distributor of
research antibodies and as Board Director of Vinnova, the Swedish
government agency that administers state funding for research and
development.
Dr Ken Cunningham, Abzena's Chairman, said:
"Lotta has a deep understanding of biomanufacturing and
development services, and how to support the needs of
biopharmaceutical companies. As a result of her strategic and
operational capability, to manage a contract development and
manufacturing service business, she will be an invaluable asset to
Abzena, as it aims to deliver value-adding services and technology
solutions to its customers."
Full name: Ingrid Charlotta ("Lotta") Ljungqvist
----------------------- ----------------------------------------
Age: 56 years old
----------------------- ----------------------------------------
Current directorships: International General Electric
Aktiebolag
North Pole Holdings AB
GECAS Sverige Aircraft Leasing
Worldwide AB
GE Renewable Sweden AB
GE Energy (Sweden) AB
GE Power Sweden AB
GE Grid Solutions AB
GE Healthcare Sverige AB
GEMS PET Systems Aktiebolag
GE Healthcare Aktiebolag
GE Healthcare Life Sciences Innovation
Center AB
GE Energy (Norway) AS
GE Healthcare AS
GE Healthcare AB
Atlas Antibodies AB
4L Bioconsulting AB
Antonov Thelander i Gimle Consulting
Aktiebolag
GE Global Holdings Denmark ApS
----------------------- ----------------------------------------
Directorships GE BioProcess R&D AB
in the last
five years:
----------------------- ----------------------------------------
Current shareholding Nil
in the Company:
----------------------- ----------------------------------------
Save as set out in this announcement, there are no further
matters to be disclosed under paragraph (g) of Schedule 2 of the
AIM Rules for Companies.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Alex 2020
Shaw / Deborah Bell abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and
recombinant proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKMGMLVRKGNZM
(END) Dow Jones Newswires
September 19, 2017 02:01 ET (06:01 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024